The present study is the first to investigate dysbindin and copper transporters as a 1 4 0 combined pathology in schizophrenia. The substantia nigra (SN) exhibits one of the highest 1 4 1 levels of copper within the brain and the highest level of the copper chaperone Atox1 (Davies et 1 4 2 al. 2013), indicating the SN has a high demand for cellular copper. Therefore, we measured 1) 1 4 3 dysbindin isoforms 1A and 1B/C, encoded by risk factor gene DTNBP1; 2) copper transporter 1 4 4 CTR1, responsible for copper transport across the BBB; 3) copper-transporting P-type ATPase, 1 4 5 ATP7A, which works in conjunction with CTR1 for intracellular copper transport; and ATP7A 1 4 6 homolog ATP7B, responsible for transfer of copper to the secretory pathway. We also conducted 1 4 7 a preliminary analysis of medication status, as there are biological correlates to medication 1 4 8 status. Our hypothesis is illustrated in Figure 1A . We hypothesize schizophrenia subjects exhibit 1 4 9 deficits in copper transport in a copper-rich brain region potentially in relation to dysbindin 1 5 0 alterations ( Figure 1B) . This work has been presented in preliminary form (Schoonover and 1 5 1 Roberts 2016). Tissue and Protein preparation 1 7 8
The SN was blocked as done previously (Schoonover et al. 2017) . In SN coronal 1 7 9 sections, caudal sections were caudal to third nerve rootlets. The blocks were trimmed to remove 1 8 0 non-nigral tissue. A perimeter of approximately 2mm of non-nigral tissue remained. Frozen 1 8 1 caudal SN was sonicated in lysis buffer (500ul/0.1g of human tissue) containing Tris-HCL (pH 1 8 2 8.0), EDTA, sodium chloride, sodium dodecyl sulfate, and a protease inhibitor cocktail (Sigma; 1 8 3 P8340). Tissue homogenate was centrifuged at 13,500 rpm for 15 mins at 4°C. Supernatant (total 1 8 4 cell lysate) was then extracted and protein concentration determined via the Lowry method (Bio-1 8 5
Rad, Hercules, CA, USA; 500-0113, 500-0114). 1 8 6
Gel electrophoresis and western blotting 1 8 7
Western blots were used to measure N-and C-terminal ATP7A, ATP7B, extracellular 1 8 8 and transmembrane CTR1, and dysbindin 1A and 1B/C protein levels and performed as 1 8 9 previously reported (Schoonover et al. 2017) , with the following exceptions. Samples intended 1 9 0 for N-terminal ATP7A assays were not heated to avoid protein aggregation. Samples intended 1 9 1 for all other assays were heated to 95ºC for 5 mins. Protein extracts (60μg) were loaded onto 4%-1 9 2 20% gradient polyacrylamide gels (Lonza, Basel, Switzerland; 58505) . Proteins were resolved by 1 9 3 sodium dodecyl sulfate-polyacrylamide gel electrophoresis at 150V for 1 hr 15 mins, and then 1 9 4 transferred at 30V for 21hrs onto polyvinylidene fluoride (PVDF) membranes (Bio-Rad, 1 9 5
Hercules, CA, USA; 162-0174) at 4ºC. Representative western blots are shown in Figure 2A ; full 1 9 6 blots are shown in Figure S1 . 1 9 7
To target potential protein segment-dependent alterations of function, we used two 1 9 8 antibodies with different epitopes for ATP7A and CTR1. The following antibodies and
concentrations were used: rabbit anti-N-terminal ATP7A, 1:500, Novus Biologicals (NBP1-2 0 0 54906); rabbit anti-C-terminal ATP7A, 1:2000, Aviva Systems Biology (ARP33798_P050); 2 0 1 rabbit anti-ATP7B, 1:1000, Abcam (ab135571); rabbit anti-transmembrane CTR1, 1:2,000, 2 0 2 Novus Biologicals (NB100-402); rabbit anti-extracellular CTR1, 1:1000, Aviva Systems Biology 2 0 3 (ARP43824_P050); rabbit anti-Dysbindin (targeting 1A and 1B/C), 1:2,000, Abcam (ab133652); 2 0 4 and mouse anti-actin, 1:40,000, Millipore (MAB1501). Each blot contained a mixture of NC and 2 0 5 schizophrenia subjects, and was performed in duplicate. The membranes were blocked for 1 hr in 2 0 6 5% milk in Tris-Buffered Saline with Tween 20 (TBST). Antigen presence was detected by 2 0 7
incubating the primary antibody with the PVDF membrane 21hrs at 4ºC. The bands were 2 0 8 visualized using chemiluminescence (Bio-Rad; 170-5018), exposing Sigma-Aldrich Carestream 2 0 9
Kodak BioMax XAR films (166-0760). 2 1 0
Experimental Controls 2 1 1
Some antibodies identified several bands; to determine the correct band to measure, we 2 1 2 conducted a preadsorption experiment for N-and C-terminal ATP7A, and extracellular and 2 1 3 transmembrane CTR1. Two identical blots containing samples from two separate controls were 2 1 4 used. One blot was incubated with primary antibody; the second blot was incubated with a 2 1 5 preadsorbed antibody mixture comprised of 1% milk containing primary antibody (the same 2 1 6 concentration as used above) that incubated for 30 minutes at room temperature with the 2 1 7 corresponding blocking peptide (1:500 concentration). The following blocking peptides were 2 1 8 used: N-terminus ATP7A, Novus Biologicals (NBP1-54906PEP); C-terminus ATP7A, Aviva 2 1 9
Systems Biology (AAP33798); transmembrane CTR1, Novus Biologicals (NB100-402PEP); and 2 2 0 extracellular CTR1, Aviva Systems Biology (AAP43824). Verifying ATP7A and CTR1 antibody 2 2 1 specificity with knockout animal models is not possible due to embryonic lethality (Menkes et al. 1962; Hua et al. 2010) . Dysbindin knockout models are viable and well-characterized (Talbot 2 2 3 2009)-additionally, it was measured at its expected molecular weight in the present study. 2 2 4 2 2 5
Analyses 2 2 6 Data 2 2 7
As described previously (Schoonover et al. 2017) , films were scanned at 600 dpi using a 2 2 8 flatbed scanner. Optical densities of the bands were measured using Image J-64 freeware (NIH). 2 2 9
A step calibration tablet was used in order to create an optical density standard curve (Stouffer 2 3 0 Industries Inc.; Mishawaka, IN, USA; T2120, series #130501) that each measurement was 2 3 1 calibrated to. ImageJ was used to perform a background subtraction for each film. All optical 2 3 2 density values for each protein were normalized to actin, and then to the averaged NC. These 2 3 3 values were averaged for duplicate samples. Demographics and tissue quality were tested using ANOVA and/or t-tests. Categorical variables 2 3 7 were assessed using a chi-square test. Outliers were detected using ROUT (Q=1.0%) and 2 3 8
Grubb's method (alpha=0.05) via Prism 7. Only one schizophrenia ATP7A value qualified for 2 3 9 removal for the schizophrenia/normal control analysis. Two schizophrenia subjects had CTR1 2 4 0 values that qualified for removal for the schizophrenia/normal control analysis and the treatment 2 Prism 7: parametric tests were followed by an uncorrected Fisher's LSD test, while 2 4 7 nonparametric tests were followed by an uncorrected Dunn's comparison. Furthermore, Brown-2 4 8
Forsythe and Bartlett's tests were used to compare standard deviations. Correlational analyses 2 4 9
were performed between results and PMI, age, years frozen, and pH to elucidate potential 2 5 0 relationships among these variables. Based on these results, years frozen was used as a covariate 2 5 1 in the dysbindin 1B/C analysis.
Demographics 2 5 4
The control (NC) and schizophrenia groups (as a whole and when subdivided by 2 5 5 treatment status) were well matched for demographic and tissue quality variables and did not
was decreased by a similar amount in both medicated (p=0.007) and unmedicated 2 7 7 schizophrenia patients (p=0.001; Figure 3D ), and there was no effect of medication on the 2 7 8 extracellular CTR1 levels. 2 7 9
Dysbindin 1A protein levels were not altered in the whole schizophrenia group or when 2 8 0 divided by treatment status (Figure 3E, 3F ). Decreased dysbindin 1B/C was observed in 2 8 1 schizophrenia subjects versus controls (p=0.046; Figure 3E ), but no effects of antipsychotics 2 8 2 were observed ( Figure 3F ). However, the significant effect was reduced to a trend when the 2 8 3 variable years frozen was implemented as a covariate (p=0.062).
8 4
No changes of ATP7B were observed in the whole schizophrenia group or when 2 8 5 subdivided by treatment status ( Figure 3G ; Figure 3H ). 2 8 6
Schizophrenia subjects treated with antipsychotic medication were further divided by 2 8 7 antipsychotic type (typical versus atypical antipsychotics). No differences were found (data not 2 8 8 shown). 2 8 9
This is the first study to investigate dysbindin and copper transporters as a combined 2 9 2 pathology in schizophrenia. Taken together, we observed protein region-specific alterations of 2 9 3 ATP7A and CTR1, some of which appear to be modulated by antipsychotic treatment. 2 9 4
Additionally, we observed isoform-specific decreases of dysbindin. These results suggest that 2 9 5 copper homeostasis is altered in schizophrenia, and merit further study. 2013). Medication history could affect our results, so we divided the schizophrenia group by 3 0 1 treatment status and type to eliminate this confounding variable. However, there were only four 3 0 2 unmedicated cases, and therefore analysis of treatment status can only be considered preliminary. 3 0 3
No differences were found between schizophrenia subjects treated with typical versus atypical 3 0 4 antipsychotics (data not shown). 1A is found in the post-synaptic density and thought to be involved in dendritic spine Other groups have also found decreases in specific isoforms in schizophrenia in various 3 2 5
brain regions, such as superior temporal gyrus (1A), dorsolateral prefrontal cortex (1C), and Based on a report of decreased copper transporters in dysbindin knockout mice (Gokhale 3 3 5 et al. 2015), we hypothesized dysregulated copper transporters CTR1 and ATP7A as a 3 3 6
consequence of downregulated dysbindin in schizophrenia subjects. While our results support 3 3 7 our hypothesis, we did not anticipate the protein-region specific alterations we observed. We 3 3 8 observed a surplus of C-, but not N-terminus, ATP7A in the whole schizophrenia group. The 3 3 9
surplus of C terminal ATP7A was significant only in medicated subjects; however, there was no 3 4 0 difference between medicated and unmedicated subjects, suggesting no effect of antipsychotic 3 4 1 drugs. However, analysis of treatment status revealed what may be an inherent deficit of N-3 4 2
terminal ATP7A in schizophrenia that is rectified with antipsychotic treatment. 3 4 3
While protein region differences ATP7A may initially seem puzzling (given that ATP7A 3 4 4
was measured at its expected molecular weight), it potentially highlights a recurring and well- Like ATP7A, we also observed domain-specific alterations of CTR1 in schizophrenia. extracellular copper binding and its transport to the cytosol, potentially resulting in decreased 3 6 5 copper transport into the cell. The mechanism behind domain-specific alterations of CTR1 in 3 6 6 schizophrenia remains untested. However, perhaps CTR1 transcription regulation is 3 6 7 pathologically altered. In yeast, CTR1 contains a copper response element (CuRE) in its 3 6 8 promoter, targeted by transcription factor Mac1, which regulates CTR1 protein expression in a potential alteration of the copper-sensing system of the metal binding domains and the cascading 3 8 0 system of phosphorylation thereafter in unmedicated schizophrenia that is potentially corrected 3 8 1 with antipsychotic treatment. Our finding of increased C-terminal ATP7A in medicated subjects
suggests further efforts by the cell to restore copper homeostasis. ATP7A is constantly recycled 3 8 3 between the plasma membrane and the TGN, but maintains a steady-state localization in the 3 8 4 TGN during normal copper conditions (Yamaguchi et al. 1993) . The carboxy terminus of the 3 8 5 protein is responsible for endocytosis from the plasma membrane to the TGN (Petris et al. 1996; 3 8 6 Petris and Mercer 1999; Francis et al. 1999) . By increasing localization of ATP7A to the TGN, 3 8 7 relatively increased copper insertion into metalloenzymes and the secretory pathway should 3 8 8 occur. 3 8 9
In brain, ATP7B moves copper from the parenchyma through the blood brain barrier to 3 9 0 the blood ( Figure 1A ). ATP7B deficits result in Wilson's disease, characterized by high copper 3 9 1 accumulation in brain and liver and low accumulation in blood (Wilson 1934) . It is therefore 3 9 2 possible that an increase in ATP7B could be causing the increases in blood copper levels often 3 9 3 reported in schizophrenia. We did not observe any alterations of the copper transporter ATP7B, 3 9 4 narrowing down the possible mechanisms by which increased blood copper in schizophrenia 3 9 5 could occur. 3 9 6 3 9 7 Implications 3 9 8
Given that ATP7A, dysbindin and CTR1 are located, in part, in the astrocytic end feet The current study provides the first evidence of abnormal brain copper homeostasis in 4 1 3 schizophrenia. Our findings suggest protein-region specific abnormalities in copper transport and 4 1 4 isoform-specific dysbindin alterations. Intracellular copper binding appears to be decreased 4 1 5 while ATP7A endocytosis mediation is increased, but only the binding is modulated by 4 1 6 antipsychotic treatment. Our results suggest extracellular copper binding and transport into the 4 1 7 cell via CTR1 is impaired in schizophrenia, and not rescued with treatment. Our findings not 4 1 8 only provide information on a potentially new pathological mechanism, but may provide a link 4 1 9 between several well-known but seemingly segregated findings in schizophrenia. Lastly, these 4 2 0 results may elucidate the paradox of excess copper in schizophrenia blood and the schizophrenia-4 2 1 like pathology that occurs in a copper-deficit state. However, schizophrenia is a complex 4 2 2 disorder and therefore copper alterations as a contributing pathology in schizophrenia merit 4 2 3 further study. Further elucidation could provide vital information about the cellular pathology of 4 schizophrenia subject on medication (SZ-ON); schizophrenia subject off medication (SZ-OFF); 4 4 7 postmortem interval (PMI); years sample has been frozen (YF); duration of illness (DUI); whole 4 4 8 sample (WS); comparison of coefficients (CC); Caucasian (C); African American (AA). Preadsorption blots for the proteins of interest. Arrows indicate the band that was measured and 4 6 0 successfully blocked in two different normal controls (S1, S2). Control blots that incubated with 4 6 1 primary antibody and no blocking peptide are shown on the left (control); preadsorbed blots are 4 6 2
shown on the right (blocking peptide). MWM, molecular weight marker. transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma 5 5 8 membrane: a novel mechanism of regulated trafficking. EMBO J. 15: 6084-6095.
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